Biome’s Activated Probiotics Launches on Fullscript, Accessing 5 Million Patients
Biome Australia has partnered with Fullscript to distribute its Activated Probiotics range across Canada, complementing its existing wholesale network and marking a key step in its international growth.
- Full Biome Activated Probiotics range approved for launch on Fullscript Canada
- Fullscript serves over 100,000 healthcare practitioners and 5 million patients in North America
- Partnership complements existing Ecotrend Ecologics wholesale distribution in Canada
- Dual-channel strategy ensures comprehensive Canadian practitioner market coverage
- Supports Biome’s Vision 27 international expansion across key global markets
Strategic Expansion into Canada’s Practitioner Market
Biome Australia Limited (ASX, BIO), a leader in microbiome health products, has announced a significant distribution partnership with Fullscript, North America's dominant digital platform for healthcare practitioners. This agreement enables Biome’s entire Activated Probiotics product range to be launched on Fullscript’s Canadian platform, with availability planned for February 2026.
Fullscript’s extensive network includes over 100,000 healthcare practitioners and reaches approximately 5 million patients across North America. This partnership provides Biome with direct access to a vast practitioner-to-patient channel, a critical avenue in the growing integrative medicine market, which has been expanding at a compound annual growth rate of 25%.
Complementing Existing Distribution for Complete Market Coverage
Biome’s move into Fullscript’s platform complements its established relationship with Ecotrend Ecologics, a leading Canadian natural health products distributor with over three decades of experience. While Ecotrend covers traditional wholesale distribution to in-clinic dispensaries, Fullscript offers a digital direct-to-patient model through e-prescribing and home delivery.
This dual-channel approach ensures that practitioners across Canada can access Biome’s Activated Probiotics regardless of their preferred dispensing method. It also navigates the stringent regulatory environment governed by Health Canada, which favours established and compliant brands.
Driving International Growth Through Vision 27
CEO Blair Norfolk highlighted the strategic importance of the Fullscript partnership, describing it as a pivotal milestone in Biome’s Canadian expansion. He emphasised that the combined distribution channels remove barriers for practitioners choosing Activated Probiotics for their patients.
Biome’s Vision 27 strategy aims to build scale across key international markets including Canada, Ireland, New Zealand, and the UK. The Fullscript partnership not only strengthens Biome’s footprint in North America but also positions the company for ongoing growth opportunities in the global microbiome health sector.
Supported by clinical research and innovative delivery technologies, Biome’s Activated Probiotics products address a range of health concerns such as mood, sleep, bone health, and digestive issues. The company’s focus on practitioner-recommended distribution channels underscores its commitment to evidence-based natural health solutions.
Bottom Line?
Biome’s dual-channel Canadian strategy sets the stage for accelerated growth but leaves questions on market penetration and competitive response.
Questions in the middle?
- How quickly will Canadian practitioners adopt Activated Probiotics via Fullscript?
- What sales growth can Biome realistically expect from the Fullscript partnership?
- How will competitors in the Canadian microbiome health market respond to Biome’s expanded presence?
